ATE393168T1 - Transkriptionsaktivierungskomplex und dessen verwendung - Google Patents

Transkriptionsaktivierungskomplex und dessen verwendung

Info

Publication number
ATE393168T1
ATE393168T1 AT01272511T AT01272511T ATE393168T1 AT E393168 T1 ATE393168 T1 AT E393168T1 AT 01272511 T AT01272511 T AT 01272511T AT 01272511 T AT01272511 T AT 01272511T AT E393168 T1 ATE393168 T1 AT E393168T1
Authority
AT
Austria
Prior art keywords
amino acid
regulatory factor
transcription regulatory
level
neurocyte
Prior art date
Application number
AT01272511T
Other languages
English (en)
Inventor
Norihisa Ohe
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Application granted granted Critical
Publication of ATE393168T1 publication Critical patent/ATE393168T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01272511T 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung ATE393168T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000398548 2000-12-27
JP2001077740 2001-03-19

Publications (1)

Publication Number Publication Date
ATE393168T1 true ATE393168T1 (de) 2008-05-15

Family

ID=26606895

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01272511T ATE393168T1 (de) 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung
AT01272819T ATE511539T1 (de) 2000-12-27 2001-12-17 Bhlh-pas-proteine, deren gene und verwendung derselben
AT01272818T ATE397664T1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT01272819T ATE511539T1 (de) 2000-12-27 2001-12-17 Bhlh-pas-proteine, deren gene und verwendung derselben
AT01272818T ATE397664T1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Country Status (6)

Country Link
US (3) US7129065B2 (de)
EP (3) EP1354889B1 (de)
AT (3) ATE393168T1 (de)
CA (3) CA2433495C (de)
DE (2) DE60134342D1 (de)
WO (3) WO2002053729A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke
WO2006026485A2 (en) 2004-08-25 2006-03-09 Isis Pharmaceuticals, Inc. Modulation of hif1-beta expression
JP2007282502A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd 細胞変性制御能力の検定方法
JP2007282501A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd アポトーシス制御能力の検定方法
US11889986B2 (en) 2010-12-09 2024-02-06 Endochoice, Inc. Flexible electronic circuit board for a multi-camera endoscope

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757524B1 (fr) * 1996-12-19 1999-01-29 Rhone Poulenc Rorer Sa Polypeptides de la famille bhlh, sequences d'acides nucleiques correspondantes
US5840532A (en) * 1997-01-21 1998-11-24 Board Of Regents, The University Of Texas System Neuronal bHLH-PAS domain proteins
WO1999028464A2 (en) 1997-11-28 1999-06-10 Wisconsin Alumni Research Foundation Cdnas and proteins belonging to the bhlh-pas superfamily of transcription regulators and methods of use
EP1307594A4 (de) * 2000-08-04 2005-05-25 Univ Florida Atlantic Zusammenhang von sim2 und krebs
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke

Also Published As

Publication number Publication date
EP1354951A4 (de) 2004-12-29
CA2433495A1 (en) 2002-07-11
DE60133774T2 (de) 2009-05-28
CA2433492A1 (en) 2002-07-11
EP1354951B1 (de) 2008-06-04
CA2433501C (en) 2011-07-19
EP1354951A1 (de) 2003-10-22
EP1354889A1 (de) 2003-10-22
US7129065B2 (en) 2006-10-31
EP1354946A1 (de) 2003-10-22
EP1354889A4 (de) 2004-12-29
US20060216705A1 (en) 2006-09-28
US20040110171A1 (en) 2004-06-10
ATE511539T1 (de) 2011-06-15
EP1354946A4 (de) 2005-01-05
EP1354946B1 (de) 2011-06-01
CA2433495C (en) 2011-10-18
WO2002053729A1 (fr) 2002-07-11
WO2002053736A1 (fr) 2002-07-11
EP1354889B1 (de) 2008-04-23
US7541189B2 (en) 2009-06-02
CA2433501A1 (en) 2002-07-11
DE60133774D1 (de) 2008-06-05
DE60134342D1 (de) 2008-07-17
US20040248247A1 (en) 2004-12-09
WO2002053735A1 (fr) 2002-07-11
ATE397664T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
ATE488588T1 (de) Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
AU4483096A (en) A method of detecting biologically active substances
DK0555205T3 (da) DNA, der koder for en væstfaktor, som er specifik for epitelceller
GB2431013A (en) Method and apparatus for sensing a time varying current passing through an ion channel
EP1170380A3 (de) Zusammensetzungen und Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
DE3851289D1 (de) Verfahren zur Züchtung rekombinanter Zellen.
WO2003078962A3 (en) Detection and quantification of modified proteins
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
ATE393168T1 (de) Transkriptionsaktivierungskomplex und dessen verwendung
WO2001042499A1 (fr) Procede d'essai d'agent curatif ou preventif de l'hyperlipemie
ATE520024T1 (de) Patch-clamp-verfahren und seine verwendung zur untersuchung subzellulärer merkmale
ATE365326T1 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
WO2009125936A3 (ko) 다낭성 난소 증후군 진단을 위한 분석방법 및 키트
ATE491037T1 (de) Verfahren zum zählen von bakterien, bakterienzählgerät und für das zählgerät vewendete zelle
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
ATE320602T1 (de) Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren
AU2001276569B2 (en) Quantitative fluorescent assay for determining the activity of transport proteins
RU2008152780A (ru) Ген, вовлеченный в иммортализацию раковой клетки человека, и его применение
WO2004079007A3 (en) Time-lapse cell analysis method
WO2003035866A1 (fr) Procede d'evaluation et d'identification de molecule biologiquement fonctionnelle a l'aide d'un gene marqueur
DE60018063D1 (de) Platform für chemische und biologische analyse mit mikrowaage, analysegerät und verfahren zur verwendung derselben
DE69635355D1 (de) Verfahren zum Nachweis von biologisch aktiven Substanzen
DE69731983D1 (de) Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren
WO2000053735A3 (en) Methods for identifying modulators of synaptic plasticity and cell motility
TW200407334A (en) Trehalose receptor and method of detecting trehalose using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties